Global Cancer Biopsy Market By Product (Instruments, Kits and Consumables, Services), By Type of Biopsy (Tissue Biopsies (Needle and Surgical Biopsies), Liquid Biopsies, Others), By Application (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer, Ovarian Cancer, Others), By End User (Reference Laboratories, Hospitals and Physician Laboratories, Academic and Research Centers), By Region, Competition Forecast & Opportunities, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 36.73 Billion
CAGR (2026-2031)	10.97%
Fastest Growing Segment	Breast Cancer
Largest Market	Asia Pacific
Market Size (2031)	USD 68.59 Billion

Market Overview

The Global Cancer Biopsy Market will grow from USD 36.73 Billion in 2025 to USD 68.59 Billion by 2031 at a 10.97% CAGR. A cancer biopsy constitutes the extraction of tissue or fluid samples for pathological examination to confirm the presence and type of malignancy. The market finds support from the escalating global prevalence of oncological disorders and the rising preference for less invasive diagnostic procedures that ensure early detection. According to the American Cancer Society, in 2024, the United States is projected to witness 2,001,140 new cancer cases. This substantial disease burden directly necessitates increased diagnostic volumes and drives the continuous demand for reliable biopsy products across healthcare systems.

However, the sector encounters notable impediments that constrain potential growth. One significant challenge impeding market expansion is the shortage of skilled pathologists and radiologists required to interpret complex samples accurately. This workforce scarcity creates diagnostic bottlenecks and limits the accessibility of essential biopsy services in regions with limited resources.

Key Market Drivers

Technological advancements in liquid biopsy modalities are fundamentally reshaping the sector by offering a minimally invasive alternative to traditional tissue extraction. This innovation allows for the detection of circulating tumor DNA (ctDNA) through a simple blood draw, facilitating real-time monitoring of disease progression and treatment response without the risks often associated with surgical procedures. The method's ability to provide comprehensive genomic profiling is driving rapid adoption among oncologists, particularly for patients where tissue accessibility is challenging or for longitudinal monitoring. This shift is evidenced by significant volume growth in the industry; according to Guardant Health, January 2025, in the 'Preliminary Fourth Quarter and Full Year 2024 Results', the company reported approximately 206,700 oncology clinical tests, representing an increase of 20% compared to the prior year, highlighting the surging clinical demand for these advanced diagnostic tools.

Concurrently, the expansion of government-led cancer screening initiatives is significantly boosting diagnostic volumes by systematizing early detection efforts across large populations. Public health bodies are increasingly implementing mandatory or recommended screening programs for high-prevalence malignancies such as breast, colorectal, and cervical cancers to reduce mortality rates through timely intervention. According to NHS England Digital, February 2025, in the 'Breast Screening Programme, England, 2023-24', the program screened 1.95 million women, successfully detecting 16,677 cancers, which underscores the massive scale of state-sponsored diagnostic activities. This proactive approach is essential given the growing disease burden; according to the World Health Organization, February 2024, there were an estimated 20 million new cancer cases globally in 2022, a statistic that reinforces the critical need for robust screening and biopsy infrastructure worldwide.

Download Free Sample Report

Key Market Challenges

The shortage of skilled pathologists and radiologists serves as a critical bottleneck that directly impedes the expansion of the Global Cancer Biopsy Market. These specialists are integral to the diagnostic workflow, responsible for both guiding precision biopsy procedures and interpreting complex tissue samples. When the workforce is insufficient to meet the rising volume of oncological cases, healthcare facilities face operational constraints that severely limit their daily diagnostic capacity. This inability to process samples efficiently creates significant backlogs and extends turnaround times for results. Consequently, the volume of biopsy procedures that can be performed and billed is effectively capped, thereby reducing the utilization rate of biopsy consumables and devices which stalls revenue generation for manufacturers.

The severity of this workforce gap is substantiated by recent industry data. According to the Royal College of Radiologists, in 2024, the clinical radiology sector faced a 30% workforce shortfall across the United Kingdom's health service. Such a deficit compels hospitals to prioritize emergency cases over routine diagnostic screenings, leading to a tangible reduction in the overall throughput of biopsy procedures. This scarcity directly restricts market growth, as the demand for diagnostic products cannot be fully realized without the necessary professionals to execute and analyze the tests.

Key Market Trends

The integration of artificial intelligence into histopathology is revolutionizing the interpretation of biopsy samples by enhancing accuracy and workflow efficiency. Algorithms trained on vast datasets of tissue images assist pathologists in identifying malignant cells with high precision, thereby reducing inter-observer variability and addressing diagnostic bottlenecks. This technological shift allows laboratories to process higher sample volumes and integrate clinical data for more comprehensive patient profiling, moving beyond traditional microscopy. According to Tempus AI, November 2024, in the 'Third Quarter 2024 Financial Results', the company reported revenue of $180.9 million, an increase of 33% year-over-year, which highlights the growing commercial adoption of AI-enabled precision medicine platforms that leverage extensive libraries of clinical and molecular data to support diagnostic decision-making.

Concurrently, the adoption of robotic-assisted platforms for tissue acquisition is establishing new standards for procedural precision and patient safety. These automated systems utilize advanced navigation and articulation capabilities to reach lesions in anatomical locations that are difficult to access via conventional manual techniques, such as the peripheral lung. By stabilizing instrument movement and providing real-time visualization, robotic platforms significantly increase the diagnostic yield of tissue samples while minimizing trauma to surrounding healthy tissue. The market traction for these systems is evident; according to Intuitive Surgical, January 2025, in the 'Fourth Quarter and Full Year 2024 Financial Results', the Ion endoluminal system saw procedure volume growth of 73% in the fourth quarter compared to the prior year, reflecting a rapid shift towards robotic interventions for complex biopsy procedures.

Segmental Insights

The breast cancer segment is positioned as the fastest-growing category within the global cancer biopsy market due to the increasing prevalence of the disease worldwide. This growth is substantially supported by established public health initiatives, such as the National Breast and Cervical Cancer Early Detection Program by the Centers for Disease Control and Prevention, which promote routine screening and early diagnosis. Additionally, the market shift toward minimally invasive biopsy techniques encourages higher patient compliance and procedural volume. These factors collectively drive the sustained demand for biopsy solutions dedicated to breast cancer detection and monitoring.

Regional Insights

Asia Pacific stands as the leading region in the Global Cancer Biopsy Market, primarily driven by a substantial patient base and the highest cancer incidence globally. This market dominance is supported by robust government initiatives promoting early detection and mass screening programs across major economies. Regulatory bodies, such as the National Medical Products Administration in China and the Pharmaceuticals and Medical Devices Agency in Japan, facilitate the rapid approval of diagnostic technologies. Additionally, continuous improvements in healthcare infrastructure and rising public awareness regarding early diagnosis further solidify the region's primary position in driving global market demand.

Recent Developments

• In September 2025, Exact Sciences Corp. launched the Cancerguard test, a new multi-cancer early detection liquid biopsy available as a laboratory-developed test in the United States. This diagnostic tool was designed to analyze multiple biomarker classes to identify signals from over 50 cancer types and subtypes, including high-mortality malignancies like pancreatic and esophageal cancers. Data from development studies demonstrated that the test achieved 68 percent sensitivity for six of the deadliest cancers and a high specificity rate. The company introduced this blood-based screening option to complement standard-of-care methods and address the significant unmet need in early cancer detection.
• In August 2024, Labcorp received De Novo marketing authorization from the U.S. Food and Drug Administration for the PGDx elio plasma focus Dx, a pan-solid tumor liquid biopsy test. This approval enabled the company to market a kitted genomic profiling solution that analyzes 33 genes associated with solid tumors using a simple blood draw. The test was designed to assist oncologists in selecting appropriate precision therapies when tissue specimens are insufficient or unavailable. The Medical Lead for Oncology at Labcorp stated that this addition to their portfolio would allow laboratories to perform comprehensive genomic profiling in-house, streamlining patient care.
• In July 2024, Guardant Health announced that the U.S. Food and Drug Administration approved its Shield blood test as a primary screening option for colorectal cancer in average-risk adults. This approval established the product as the first blood-based test to meet the performance requirements for Medicare coverage in this indication. The decision was supported by clinical study results showing the test achieved 83 percent sensitivity for detecting colorectal cancer. The co-CEO of Guardant Health emphasized that this non-invasive liquid biopsy offering would help overcome adherence barriers associated with traditional screening methods such as colonoscopies and stool-based tests.
• In March 2024, Thermo Fisher Scientific Inc. and Bayer AG entered into a collaboration to develop next-generation sequencing-based companion diagnostic assays. The partnership aimed to leverage the Ion Torrent Genexus Dx System to identify patients eligible for precision cancer therapies through rapid genomic testing. The companies planned to co-develop assays that could deliver results from tumor or liquid biopsy samples in approximately 24 hours. A senior executive at Thermo Fisher Scientific highlighted that this cooperation would facilitate decentralized testing, ensuring that eligible patients can be quickly matched with targeted treatments based on their unique biomarker profiles.

Key Market Players

• QIAGEN N.V.
• Illumina, Inc.
• Guardant Health, Inc.
• Thermo Fisher Scientific, Inc.
• F. Hoffmann-La Roche Ltd.
• Myriad Genetics, Inc.
• Exact Sciences Corporation
• GRAIL, LLC
• Lucence Diagnostics Pte. Ltd.
• ANGLE plc

By Product	By Type of Biopsy	By Application	By End User	By Region
Instruments Kits and Consumables Services	Tissue Biopsies (Needle and Surgical Biopsies) Liquid Biopsies Others	Breast Cancer Colorectal Cancer Lung Cancer Prostate Cancer Pancreatic Cancer Ovarian Cancer Others	Reference Laboratories Hospitals and Physician Laboratories Academic and Research Centers	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Cancer Biopsy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Cancer Biopsy Market, By Product:

• Instruments
• Kits and Consumables
• Services

• Cancer Biopsy Market, By Type of Biopsy:

• Tissue Biopsies (Needle and Surgical Biopsies)
• Liquid Biopsies
• Others

• Cancer Biopsy Market, By Application:

• Breast Cancer
• Colorectal Cancer
• Lung Cancer
• Prostate Cancer
• Pancreatic Cancer
• Ovarian Cancer
• Others

• Cancer Biopsy Market, By End User:

• Reference Laboratories
• Hospitals and Physician Laboratories
• Academic and Research Centers

• Cancer Biopsy Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE